The Impact of Discordance Between Biopsy and Pathological Gleason Scores on Survival After Radical Prostatectomy

Journal of Urology

Volumn 181, Issue 1, 2009, Pages 95-104

  Boorjian, Stephen A ^a   Karnes, R Jeffrey ^a   Crispen, Paul L ^a   Rangel, Laureano J ^a   Bergstralh, Eric J ^a   Sebo, Thomas J ^a   Blute, Michael L ^a  

^a MAYO CLINIC COLLEGE OF MEDICINE   (United States)

Author keywords

biopsy; prostate; prostate specific antigen; prostatectomy; prostatic neoplasms

Indexed keywords

ARTICLE; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; CLINICAL EVALUATION; DISEASE ASSOCIATION; GLEASON SCORE; HUMAN; LYMPH NODE METASTASIS; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY;

AGED; BIOPSY; HUMANS; MALE; MIDDLE AGED; PROSTATECTOMY; PROSTATIC NEOPLASMS; SURVIVAL RATE;

EID: 57249088912     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2008.09.016     Document Type: Article

References (20)

1. Makarov D.V., Trock B.J., Humphreys E.B., Mangold L.A., Walsh P.C., Epstein J.I., et al. Updated nomogram to predict pathologic stage of prostate cancer given prostate- specific antigen level, clinical stage, and biopsy Gleason score (Partin tables) based on cases from 2000 to 20005. Urology 69 (2007) 1095
2. D'Amico A.V., Whittington R., Malkowicz S.B., Schultz D., Schnall M., Tomaszewski J.E., et al. A multivariate analysis of clinical and pathological factors that predict for prostate specific antigen failure after radical prostatectomy for prostate cancer. J Urol 154 (1995) 131
3. D'Amico A.V., Cote K., Loffredo M., Renshaw A.A., and Chen M.H. Pretreatment predictors of time to cancer specific death after prostate specific antigen failure. J Urol 169 (2003) 1320
4. Freedland S.J., Humphreys E.B., Mangold L.A., Eisenberger M., Dorey F.J., Walsh P.C., et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 294 (2005) 433
5. Steinberg D.M., Sauvageot J., Piantadosi S., and Epstein J.I. Correlation of prostate needle biopsy and radical prostatectomy Gleason grade in academic and community settings. Am J Surg Pathol 21 (1997) 566
6. King C.R., McNeal J.E., Gill H., and Presti Jr. J.C. Extended prostate biopsy scheme improves reliability of Gleason grading: implications for radiotherapy patients. Int J Radiat Oncol Biol Phys 59 (2004) 386
7. Donohue J.F., Bianco Jr. F.J., Kuroiwa K., Vickers A.J., Wheeler T.M., Scardino P.T., et al. Poorly differentiated prostate cancer treated with radical prostatectomy: long-term outcome and incidence of pathological downgrading. J Urol 176 (2006) 991
8. Pinthus J.H., Witkos M., Fleshner N.E., Sweet J., Evans A., Jewett M.A., et al. Prostate cancers scored as Gleason 6 on prostate biopsy are frequently Gleason 7 tumors at radical prostatectomy: implication on outcome. J Urol 176 (2006) 979
9. Fine S.W., and Epstein J.I. A contemporary study correlating prostate needle biopsy and radical prostatectomy Gleason score. J Urol 179 (2008) 1335
10. Gonzalgo M.L., Bastian P.J., Mangold L.A., Trock B.J., Epstein J.I., Walsh P.C., et al. Relationship between primary Gleason pattern on needle biopsy and clinicopathologic outcomes among men with Gleason score 7 adenocarcinoma of the prostate. Urology 67 (2006) 115
11. Fitzsimons N.J., Presti Jr. J.C., Kane C.J., Terris M.K., Aronson W.J., Amling C.L., et al. Is biopsy Gleason score independently associated with biochemical progression following radical prostatectomy after adjusting for pathological Gleason score?. J Urol 176 (2006) 2453
12. Müntener M., Epstein J.I., Hernandez D.J., Gonzalgo M.L., Mangold L., Humphreys E., et al. Prognostic significance of Gleason score discrepancies between needle biopsy and radical prostatectomy. Eur Urol 53 (2008) 767
13. Ward J.F., Blute M.L., Slezak J., Bergstralh E.J., and Zincke H. The long-term clinical impact of biochemical recurrence of prostate cancer 5 or more years after radical prostatectomy. J Urol 170 (2003) 1872
14. Albertsen P.C., Hanley J.A., Gleason D.F., and Barry M.J. Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer. JAMA 280 (1998) 975
15. Blute M.L., Bergstralh E.J., Iocca A., Scherer B., and Zincke H. Use of Gleason score, prostate specific antigen, seminal vesicle and margin status to predict biochemical failure after radical prostatectomy. J Urol 165 (2001) 119
16. Sebo T.J., Cheville J.C., Riehle D.L., Lohse C.M., Pankratz V.S., Myers R.P., et al. Perineural invasion and MIB-1 positivity in addition to Gleason score are significant preoperative predictors of progression after radical retropubic prostatectomy for prostate cancer. Am J Surg Pathol 26 (2002) 431
17. Stamey T.A., Yemoto C.M., McNeal J.E., Sigal B.M., and Johnstone I.M. Prostate cancer is highly predictable: a prognostic equation based on all morphological variables in radical prostatectomy specimens. J Urol 163 (2000) 1155
18. Sim H.G., Telesca D., Culp S.H., Ellis W.J., Lange P.H., True L.D., et al. Tertiary Gleason pattern 5 in Gleason 7 prostate cancer predicts pathological stage and biochemical recurrence. J Urol 179 (2008) 1775
19. Kang D.E., Fitzsimons N.J., Presti Jr. J.C., Kane C.J., Terris M.K., Aronson W.J., et al. Risk stratification of men with Gleason score 7 to 10 tumors by primary and secondary Gleason score: results from the SEARCH database. Urology 70 (2007) 277
20. Sengupta S., Slezak J.M., Blute M.L., Leibovich B.C., Sebo T.J., Myers R.P., et al. Trends in distribution and prognostic significance of Gleason grades on radical retropubic prostatectomy specimens between 1989 and 2001. Cancer 106 (2006) 2630